SEOUL, Jan. 9 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. said Monday it has signed a contract with Rani Therapeutics, a U.S. bio firm, to cooperate in developing an oral antibody medication. RT-111 is Rani’s project to develop ustekinumab, sold under the name of Stelara by Janssen Pharmaceuticals for the treatment of Crohn’s [...]
SEOUL, Sept. 27 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. said Tuesday it has received approval to sell its anticancer biosimilar Vegzelma in Japan. According to the company, Japan’s Ministry of Health, Labor and Welfare recently approved the sale of the biosimilar, also known as CT-P16, which referenced Switzerland-based Roche Holding’s blockbuster pill [...]
SEOUL, Sept. 21 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. said Wednesday it has signed a deal to jointly develop a bispecific breast cancer treatment candidate of Abpro Corp. of the United States. Under the deal, Celltrion and Abpro will work together for the development and market release of breast cancer treatment candidate [...]
SEOUL, Aug. 22 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. has opened a research and development (R&D) office in Boston to help accelerate its new drug development capabilities in the United States, according to company officials Monday. Celltrion completed the establishment of the Boston R&D office earlier this year and hired local office [...]
SEOUL, Aug. 19 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical firm, said Friday it has secured a 110 billion-won (US$83 million) drug substance supply deal from Teva Pharmaceutical Industries Ltd. for use in producing the Israel-based generic drugmaker’s migraine medicine. Under the contract manufacturing organization (CMO) deal, Celltrion will provide drug substance [...]
SEOUL, April 27 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Wednesday it will begin sales of its autoimmune disease biosimilar Yuflymain in the United States in July 2023. The plan comes as Celltrion has settled a patent dispute with U.S. drugmaker AbbVie Inc. Yuflyma — a biosimilar referencing blockbuster drug Humira — [...]
SEOUL, March 2 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Wednesday that its autoimmune disease biosimilar Yuflyma has begun sales in the domestic market. Yuflyma — a biosimilar referencing blockbuster drug Humira by AbbVie Inc. — is used to treat patients with multiple chronic inflammatory diseases, such as rheumatoid arthritis and psoriasis. [...]
SEOUL, Feb. 24 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. on Thursday anticipated its antibody treatment against COVID-19 under development would show efficacy against the omicron variant. Celltrion said that CT-P63 has maintained strong neutralizing ability against the omicron variant during pseudo-virus testing. The candidate treatment is currently under clinical trials. The announcement [...]
SEOUL, Feb. 22 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Tuesday that a high-concentration version of its autoimmune disease biosimilar Yuflyma has won approval from European drug authorities. The European Medicines Agency (EMA) gave the green light to Celltrion’s application to sell Yuflyma — a biosimilar referencing blockbuster drug Humira by AbbVie [...]
SEOUL, Feb. 16 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical firm, said Wednesday that its net profit jumped 20.1 percent on-year last year on the back of robust sales of its biosimilar products in overseas markets. Net profit came to 623.7 billion won (US$521.1 million) last year on a consolidated basis, compared [...]